ArticleJugan geon-gang gwa jilbyeong2023
Article in Jugan geon-gang gwa jilbyeong, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Impacts of relaxed mask policies on COVID-19 epidemics: a modeling study in South Korea.BMC infectious diseases · 2026Article
- COVID-19 Vaccination Strategy and Evidence in Korea.Journal of Korean medical science · 2026Review
- Excess mortality and healthcare costs during the COVID-19 pandemic among patients with ten major chronic diseases in South korea: a nationwide analysis.BMC infectious diseases · 2025Observational
- COVID-19 severity analysis for clinical decision support based on machine learning approach.Scientific reports · 2025Article
- Pandemic Preparation and Response in Long-Term Care Hospitals: Lessons from COVID-19 Outbreaks and Preparedness for Future Infectious Diseases.Annals of geriatric medicine and research · 2025Article
- Impact of imported COVID-19 cases on South Korea's response: variant transitions and regional patterns (2020-2023).BMC infectious diseases · 2025Article
- Reinfection of SARS-CoV-2 Variants in Immunocompromised Patients with Prolonged or Relapsed Viral Shedding.Infection & chemotherapy · 2025Article
- Initial and peak serum levels of Krebs von den Lungen-6 for predicting the prognosis of patients with COVID-19.The Korean journal of internal medicine · 2025Article
- Characteristics and trends of severe/critical COVID-19 cases in the Republic of Korea (January 2020 to August 2023).Osong public health and research perspectives · 2025Article
- [Characteristics and Trends of Coronavirus Disease 2019 Outbreak in the Republic of Korea (January 20, 2020-August 30, 2023)].Jugan geon-gang gwa jilbyeong · 2025Article
- Machine learning-based approach to guide the choice between baricitinib and tocilizumab in critical COVID-19 pneumonia treatment: a retrospective cohort study.Frontiers in medicine · 2025Article
- Risk of new-onset seizures following immunization against COVID-19: a self-controlled case-series study.Epidemiology and health · 2025Article
- Estimating Excess Mortality During the COVID-19 Pandemic Between 2020-2022 in Korea.Journal of Korean medical science · 2024Article
- Risk of nosocomial coronavirus disease 2019: comparison between single- and multiple-occupancy rooms.Antimicrobial resistance and infection control · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This report seeks to compare and analyze the severity trends of coronavirus disease 2019 (COVID-19) in Republic of Korea during periods of dominant variant virus prevalence. The analysis covers the period from January 20, 2020, to July 31, 2023, categorizing the severity of COVID-19 cases both throughout the entire period and during periods of dominant variant virus prevalence. Up until July 31, 2023, a total of 34,082,179 confirmed cases of COVID-19 have been recorded, resulting in 37,760 cases (0.11%) of severe illness and 35,644 deaths (0.11%). During the dominant prevalence of the Omicron BA.1 and BA.2 variants (from January 16, 2022 to July 9, 2022), severe cases and deaths were most widespread, accounting for 10,460 cases (27.7%) of severe illness and 18,679 deaths (52.4%). Concerning case severity rate and case fatality rate, the period before the dominant prevalence of the Delta variant (from January 20, 2020 to July 24, 2021) had the highest rates at 2.98% and 1.15%, respectively. In contrast, during the dominant prevalence of the Omicron XBB variant (from April 16, 2023 to July 31, 2023), these rates were at their lowest, reaching 0.12% for severity and 0.04% for fatality. Despite the continuous emergence of new variant viruses after the onset of COVID-19, the case severity rate during the dominant prevalence of the Omicron XBB variant has decreased to 0.04%, comparable to the risk level seen with influenza. However, the case fatality rate by age group is <0.01% for 0-49 years old, 0.01% for 50-59 years old, and 0.03% for 60-69 years old, while the case fatality rate for 80+ years old is 0.56%, which is still higher than other age groups, so the prevention policy of prioritizing high-risk groups should be continued.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.